CRISPR Therapeutics AG (LTS:0VRQ) Accumulated Depreciation: $ Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0VRQ CRISPR Therapeutics AG LTS:0VRQ
37 GF Score
Price $58.33
GF Value $5.68
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Accumulated Depreciation?

CRISPR Therapeutics AG LTS:0VRQ -1.57% 37 Accumulated Depreciation is $ Mil as of Jun. 2026. GuruFocus rates LTS:0VRQ with a GF Score™ of 37/100 and a GF Value™ of $5.68 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

CRISPR Therapeutics AG's annual accumulated depreciation increased from Dec. 2023 ($-53.43 Mil) to Dec. 2024 ($-72.27 Mil) and increased from Dec. 2024 ($-72.27 Mil) to Dec. 2025 ($-91.05 Mil).

CRISPR Therapeutics AG Accumulated Depreciation Related Terms

CRISPR Therapeutics AG Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG Accumulated Depreciation Chart

CRISPR Therapeutics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -37.81 -33.83 -53.43 -72.27 -91.05

CRISPR Therapeutics AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
LTS:0VRQ
37GF Score
CRISPR Therapeutics AG LTS:0VRQ
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $ Mil mean?
CRISPR Therapeutics AG (LTS:0VRQ) has a Accumulated Depreciation of $ Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Accumulated Depreciation too high?
CRISPR Therapeutics AG's current Accumulated Depreciation is $ Mil. Overall, CRISPR Therapeutics AG has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Accumulated Depreciation compare to LGND and DFTX?
CRISPR Therapeutics AG's Accumulated Depreciation of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Accumulated Depreciation is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.68, compared to a current price of $58.33 — trading 926.9% above its estimated fair value. The current Accumulated Depreciation is $ Mil. CRISPR Therapeutics AG's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current Accumulated Depreciation is $ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CRISPR Therapeutics AG (LTS:0VRQ) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of $58.33 is trading 926.9% above its estimated GF Value™ of $5.68. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for LTS:0VRQ:

  • Accumulated Depreciation: $ Mil
  • GF Value™: $5.68 vs. price of $58.33 (926.9% above fair value)
  • GF Score™: 37/100 with 2 warning signs

No single metric tells the full story. See the LTS:0VRQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
CRISPR Therapeutics AG is a Swiss biopharmaceutical company focused on developing gene-editing medicines based on CRISPR/Cas9 technology, which enables precise modification of genomic DNA. Its lead product, Casgevy, was developed with Vertex Pharmaceuticals and is approved for sickle cell disease and transfusion-dependent beta-thalassemia. The company also advances programs in immuno-oncology, cardiovascular disease, and a stem-cell-derived therapy for type 1 diabetes, alongside in vivo editing approaches. CRISPR Therapeutics conducts research and development across sites in Switzerland, the United States, and Canada, and generates revenue through collaboration and licensing agreements, including with Vertex, as well as potential product sales. Its pipeline spans both ex vivo cell therapies and in vivo treatments targeting genetically defined diseases.
37GF Score

Get the complete analysis for LTS:0VRQ

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$58.33
Price
$5.68
GF Value